HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

A Different View on Global CDMO - The Industry Trend, the Major Players, and the Outlook

Sino Biopharmaceutical (1177.HK) - The Positives and the Negatives

Pre-IPO Changchun BCHT Biotechnology - The Risk of Single-Product Dependence and Uncertain Outlook

China Traditional Chinese Medicine (570.HK) - The Privatization Rumor and the Outlook

Equity Capital Markets

Beijing Luzhu Biotechnology / Equity Capital Markets

Beijing Luzhu Biotechnology (1868402D CH)

<ul>
<li>Either vaccines or therapeutic biologics, Luzhu’s clinical progress has no advantages. There have been quite a few competing products on the market or candidates with faster development progress than Luzhu.</li>
<li>Luzhu applies the low price strategy to open the market. We're not sure if it works or not, since it still depends on R&amp;D efficiency, product quality and commercialization capabilities.</li>
<li>We tend to be conservative about the Company's prospects because its eventual revenue scale and profit margins are likely to be very limited based on our analysis.</li>
</ul>


Either vaccines or therapeutic biologics, Luzhu’s clinical progress has no advantages. There have been quite a few competing products on the market or candidates with faster development progress than Luzhu.
Luzhu applies the low price strategy to open the market. We're not sure if it works or not, since it still depends on R&amp;D efficiency, product quality and commercialization capabilities.
We tend to be conservative about the Company's prospects because its eventual revenue scale and profit margins are likely to be very limited based on our analysis.


Changchun BCHT Biotechnology C (688276 CH)

Pre-IPO Beijing Luzhu Biotechnology - The Eventual Revenue Scale and Profit Margins Could Be Limited